SMMT
Summit Therapeutics Inc
$1
Earnings Summary
Revenue | $0.25Mn |
Net Profits | $-21.4Mn |
Net Profit Margins | -8558.8% |
Highlights
Summit Therapeutics Inc’s revenue jumped 30.21% since last year same period to $0.25Mn in the Q2 2022. On a quarterly growth basis, Summit Therapeutics Inc has generated -0.4% fall in its revenue since last 3-months.
Summit Therapeutics Inc’s net profit fell -22.35% since last year same period to $-21.4Mn in the Q2 2022. On a quarterly growth basis, Summit Therapeutics Inc has generated 21.04% jump in its net profits since last 3-months.
Summit Therapeutics Inc’s net profit margin jumped 6.03% since last year same period to -8558.8% in the Q2 2022. On a quarterly growth basis, Summit Therapeutics Inc has generated 20.73% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Summit Therapeutics Inc post its latest quarter earnings
EPS Estimate Current Quarter | -0.27 |
EPS Estimate Current Year | -0.27 |
Highlights
Summit Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.27 - a 6.9% jump from last quarter’s estimates.
Summit Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.27.
Key Ratios
Key ratios of the Summit Therapeutics Inc post its Q2 2022 earnings
Earning Per Share (EPS) | -0.22 |
Highlights
Summit Therapeutics Inc’s earning per share (EPS) jumped 79.22% since last year same period to -0.22 in the Q2 2022. This indicates that the Summit Therapeutics Inc has generated 79.22% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2022-03-17 | -0.27 | -0.28 | -2.37% |
Company Information
Summit Therapeutics, empowered by its Discuva Platform, the Company's innovative antibiotic discovery engine, led by Dr. Ventzislav Stefanov and supported by BARDA and Carb-X funding, intends to be the leader in patient and physician friendly paradigm shifting antibiotic innovation. Its new mechanism antibiotics are designed to become the patient-friendly, new era standard-of-care, by working in harmony with the human microbiome to treat prospective patients suffering from infectious disease, initially focussing on Clostridioides difficile infections ("CDI") which is estimated to impact over 3 million patients worldwide annually. Commercialization of ridinilazole for the treatment of CDI is subject to regulatory approvals. The overriding objective of Summit Therapeutics is to create value for patients, hospital infectious disease care givers, community based infectious disease healthcare providers, as well as healthcare payors around the world. Currently, Summit's lead product candidate ridinilazole is engaged in two global phase III trials, Ri-CoDIFy 1 & 2, each enrolling 680 patients vs standard of care (Vancomycin) for the treatment of C. difficile infections.
Organisation | Summit Therapeutics Inc |
Employees | 80 |
Industry | Health Technology |